Closing remarks
EHA Learning Center, Session Speakers, 259757
An introduction to CAR-T cell therapy
EHA Learning Center, Michael Hudecek, 261163
The supply chain for industry-manufactured autologous CAR-T cell from a hospital perspective
EHA Learning Center, Christian CHABANNON, 261164
Long term follow-up after gene / cell therapy
EHA Learning Center, JohannaB van Biezen, 261165
The Cell Therapy Form in the EBMT Registry
EHA Learning Center, Elvira Carmen De Ruiz, 261166
The EMA Initiative on Registries
EHA Learning Center, Eoin McGrath, 261167
Issues with Centre selection and Qualification/Onboarding -- The Challenge of developing Centres of Excellence in Cell and Gene Therapy
EHA Learning Center, Tony Pagliuca, 261168
Patients perspectives
EHA Learning Center, Natacha Bolaños, 261169
Patients perspectives
EHA Learning Center, Bregje Verhoeven, 261170
Reimbursement II
EHA Learning Center, Cornelie Haag, 261171
Evaluation & Preparation of Pediatric Patients for CAR T-Cell Treatment
EHA Learning Center, Daphna Hutt, 261172
CAR-T cells: Lille University Hospital experience
EHA Learning Center, Ibrahim Yakoub-Agha, 261173
An introduction to CAR-T cell therapy
EHA Learning Center, Michael Hudecek, 261174
The supply chain for industry-manufactured autologous CAR-T cell from a hospital perspective
EHA Learning Center, Christian CHABANNON, 261175
Management of complications
EHA Learning Center, Max Topp, 261176
The Dutch experience for clinical implementation of CAR T cells
EHA Learning Center, Monique Minnema, 261177
Issues with Centre selection and Qualification/Onboarding -- The Challenge of developing Centres of Excellence in Cell and Gene Therapy
EHA Learning Center, Tony Pagliuca, 261178
Patients perspectives
EHA Learning Center, Natacha Bolaños, 261179
Patients perspectives
EHA Learning Center, Bregje Verhoeven, 261180
Session 7: Best Abstracts & Flash Talks - Part II
EHA Learning Center, Session Speakers, 259738
Session 6: Keynote
EHA Learning Center, Carl June, 259737
Reimbursement
EHA Learning Center, Cornelie Haag, 261155
Celgene Cellular Therapy - Bold Innovation Delivered to Patients
EHA Learning Center, Stanley Frankel, 261156
CAR T-cell Therapy for Childhood Solid Tumours
EHA Learning Center, Karin Straathof, 261152
Cars, TRUCKs and beyond: the next generation of CAR T cells
EHA Learning Center, Hinrich Abken, 261153
New targets and technologies for CAR-T H
EHA Learning Center, Michael Hudecek, 261154
CART-Ts are rolling into the clinic - the Wurzburg experience
EHA Learning Center, Michael Hudecek, 261157
CART19-BE-01 trial: an update
EHA Learning Center, Julio Delgado, 261158
CD44v6 CAR-T
EHA Learning Center, Fabio Ciceri, 261159
The Real Deal - Effectiveness, Value, & Outcomes using RWE CAR-T for ALL
EHA Learning Center, Duane Schulthess, 261160
CAR-T TREATMENT FOR R/R B-CELL ALL: Experience from China
EHA Learning Center, Peihua Lu, 261161
Non-Viral Genetic Engineering of Cytokine-Induced Killer (CIK) Cells with Chimeric Antigen Receptors (CARs) for the Targeting of Acute Myeloid Leukemia
EHA Learning Center, Sarah Tettamanti, 261162
CAR T cells – a regulatory view from the EMA Committee for Advanced Therapies
EHA Learning Center, Martina Schüssler-Lenz, 261699
Taking CAR-T from theory to reality - the Novartris experience
EHA Learning Center, Emanuele Ostuni, 261700
Best Abstracts & Flash Talks - Part I
EHA Learning Center, Session Speakers, 259735
Opening & welcome
EHA Learning Center, Session Speakers, 259730
Chimeric Antigen Receptor T-Cell Therapy Acute Myeloid Leukemia: Targeting CD123
EHA Learning Center, Elizabeth Budde, 261697
CAR T Cell Therapy for Multiple Myeloma
EHA Learning Center, Alfred Le Roy Garfall III, 261696
How to use CAR T cells in Multiple Myeloma?
EHA Learning Center, Hermann Einsele, 261698
UCL CAR T-Cell Programme - focus on CD19
EHA Learning Center, Claire Roddie, 261147
CAR T-cells in DLBCL: hype or hope
EHA Learning Center, Marie Jose Kersten, 261148
Improving outcomes of therapy with CAR T cells
EHA Learning Center, Stanley Riddell, 261149
Academic CAR T cell trials for pediatric patients in Europe
EHA Learning Center, Franco Locatelli, 261150
Real Life Experience in the Treatment of Pediatric, Adolescent and Young Adult ALL Patients Using Commercially Avaolable CAR-T cells
EHA Learning Center, Peter Bader, 261151
Expert interview with Jason Gotlib
EHA Learning Center, Jason R. Gotlib, 256798
Expert interview with James Ferrara
EHA Learning Center, James Ferrara, 256799
Expert interview with David Weinstock
EHA Learning Center, David Weinstock, 256800
Expert interview with Charles Craddock
EHA Learning Center, Charles Craddock, 256801
Expert interview with Sergio Giralt
EHA Learning Center, Sergio Giralt, 256802
Expert interview with Michael Pulsipher
EHA Learning Center, Michael Pulsipher, 256803
Expert interview with Loretta Nastoupil
EHA Learning Center, Loretta Nastoupil, 256804
Expert interview with Ann Mullally
EHA Learning Center, Ann Mullally, 256805
Expert interview with Alex Herrera
EHA Learning Center, Alex Herrera, 256806
Expert interview with Laura Micharlis
EHA Learning Center, Laura Micharlis, 256807
MOA and Manufacturing of CAR T-cell Therapy
EHA Learning Center, Delivered by Novartis, 234312
Alas1 Is Essential For Neutrophil Maturation In Zebrafish
EHA Learning Center, Junwei Lian, 234395
The SLC40A1 R178Q Mutation Is A Recurrent Cause Of Hemochromatosis And Is Associated With A Novel Pathogenic Mechanism
EHA Learning Center, Chandran Ka, 234396
Novel Lineage Depletion Preserves Autologous Blood Stem Cells For Gene Therapy Of Fanconi Anemia Complementation Group A
EHA Learning Center, Jennifer E. Adair, 234397
Prognostic Factors Of Erdheim–Chester Disease: A Nationwide Survey In Japan
EHA Learning Center, Takashi Toya, 234398
Reduced Tyrosine Kinase Inhibitor Dose Is Predicted To Be As Effective As Standard Dose In Chronic Myeloid Leukemia: A Simulation Study Based On Phase III Trial Data
EHA Learning Center, Artur C. Fassoni, 234399
Inhibition Of Protein Disulfide Isomerase Induces Differentiation Of Acute Myeloid Leukemia Cells
EHA Learning Center, Justyna Chlebowska-Tuz, 234400
MDM2- And FLT3-Inhibitors In The Treatment Of FLT3-ITD Acute Myeloid Leukemia, Specificity And Efficacy Of NVP-HDM201 And Midostaurin
EHA Learning Center, Katja Seipel, 234401
Adherence To The Western, Prudent, And Mediterranean Dietary Patterns And Chronic Lymphocytic Leukemia In The MCC-Spain Study
EHA Learning Center, Marta Solans, 234402
Inferior Survival In High-Grade B-Cell Lymphoma With MYC And BCL2 And/Or BCL6 Rearrangements Is Not Associated With MYC/IG Gene Rearrangements
EHA Learning Center, Ellen D. McPhail, 234403
PD-L1+ Tumor-Associated Macrophages And PD-1+ Tumor-Infiltrating Lymphocytes Predict Survival In Primary Testicular Lymphoma
EHA Learning Center, Marjukka Pollari, 234404
A Phase II/III Randomized, Multicenter Trial Of Prednisone/Sirolimus Versus Prednisone/ Sirolimus/Calcineurin Inhibitor For The Treatment Of Chronic Graft-Versus-Host Disease: BMT CTN 0801
EHA Learning Center, Paul A. Carpenter, 234405
N-Linked Glycosylation Modulates The Immunogenicity Of Recombinant Human Factor VIII In Hemophilia A Mice
EHA Learning Center, Jesse D. Lai, 234406
Treatment-Free Remission After Two-Year Consolidation Therapy With Nilotinib In Patients With Chronic Myeloid Leukemia: STAT2 Trial In Japan
EHA Learning Center, Naoto Takahashi, 234407
Radiation Exposure From Computerized Tomography And Risk Of Childhood Leukemia: Finnish Register-Based Case-Control Study Of Childhood Leukemia (FRECCLE)
EHA Learning Center, Atte Nikkilä, 234408
Genetics Of Acute Myeloid Leukemia In The Elderly: Mutation Spectrum And Clinical Impact In Intensively Treated Patients Aged 75 Years Or Older
EHA Learning Center, Victoria Prassek, 234409
Safety Of Obinutuzumab Alone Or Combined With Chemotherapy For Previously Untreated Or Relapsed/Refractory Chronic Lymphocytic Leukemia In The Phase IIIb GREEN Study
EHA Learning Center, Véronique Leblond, 234410
SCD - Interactive Content
EHA Learning Center, Delivered by Novartis, 234217
Sickle Cell Disease - VOC pathophysiology
EHA Learning Center, Delivered by Novartis, 234216
Managing CLL Patients In 2018: Updates From The Recent ASH Congress
EHA Learning Center, Delivered by Janssen, 233813
Interpreting ASH 2017 updates for your daily clinical practice a roundtable discussion on MM
EHA Learning Center, Delivered by Janssen, 233812
Thrombosis The basics
EHA Learning Center, Roger Schutgens, 233293
Repopulating hematopoietic stem cells from steady-state blood before and after ex vivo culture are enriched in the CD34+CD133+CXCR4low fraction
EHA Learning Center, Véronique Lapostolle, 234239
Circulating iron levels influence the regulation of hepcidin following stimulated erythropoiesis
EHA Learning Center, Cornel S.G. Mirciov, 234240
Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice
EHA Learning Center, Xin Jin, 234241
Bone marrow histomorphological criteria can accurately diagnose hemophagocytic lymphohistiocytosis
EHA Learning Center, Eric Gars, 234242
Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
EHA Learning Center, Weiguo Zhang, 234243
Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial
EHA Learning Center, Alan K Burnett, 234244
Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients
EHA Learning Center, Ibrahim Aldoss, 234245
CDCA7 is a critical mediator of lymphomagenesis that selectively regulates anchorage-independent growth
EHA Learning Center, Raúl Jiménez-P, 234246
Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies
EHA Learning Center, Mara M. Epstein, 234247
Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation
EHA Learning Center, Ailing Liu, 234248
The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial
EHA Learning Center, Helene M. Schoemans, 234249
Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated
EHA Learning Center, Sarah Nikiforow, 234250
CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice
EHA Learning Center, Brent A. Williams, 234251
Cytoprotective and pro-angiogenic functions of thrombomodulin are preserved in the C loop of the fifth epidermal growth factor-like domain
EHA Learning Center, xiangmin wang, 234252
A subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation
EHA Learning Center, Maaike Rijkers, 234253
Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia
EHA Learning Center, Stefanie Geyh, 234226
Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells
EHA Learning Center, Dang Wu, 234227
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study
EHA Learning Center, Natasha K.A. van Eijkelenburg, 234228
Investigating chemoresistance to improve sensitivity of childhood T-cell acute lymphoblastic leukemia to parthenolide
EHA Learning Center, Benjamin C. Ede, 234229
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
EHA Learning Center, Paul M. Barr, 234230
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
EHA Learning Center, Anthony R. Mato, 234231
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
EHA Learning Center, Jesús F. San-Miguel, 234232
Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects
EHA Learning Center, Daniel Fuerst, 234233
Patient-reported outcomes and health status associated with chronic graft-versus-host disease
EHA Learning Center, Stephanie Lee, 234234

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings